



LifePearl[®]
Microspheres

BECAUSE
EXPERIENCE
MATTERS



INTERVENTIONAL
SYSTEMS

PRE-CLINICAL EVIDENCE


ENHANCED SUSPENSION CHARACTERISTICS

LifePearl maximizes time in suspension after loading with Doxorubicin and Irinotecan which may optimize catheter deliverability^{1,2,3}

TIME IN SUSPENSION WITH IRINOTECAN²




TIME IN SUSPENSION WITH DOXORUBICIN³



Note: Values presented as means ± standard deviation

TIGHT CALIBRATION

LifePearl has shown tight calibration that may offer a controlled and targeted embolisation^(1,2,3)



Diameter distribution histograms of unloaded (a) and irinotecan-loaded (b) LifePearl microspheres.

LIFEPEARL MICROSPHERES CLINICAL

POSITIVE CLINICAL AND SAFETY RESULTS

Initial clinical results suggest that chemoembolisation with LifePearl is efficacious and safe for the treatment of liver cancer as indicated by **good tolerability, quality of life and high tumor response**¹

Tumour response in patients treated with LIFIRI® or LIFDOX®¹

	N	%	CR	%	PR	%
HCC	10	50	8	80	2	20
CHOLANGIO	4	20	2	50	2	50
CRC-LM	4	20	1	25	3	75
U-LM	1	5	1	100	0	0
BC-LM	1	5	0	0	1	100

HCC, Hepatocellular carcinoma - CHOLANGIO, Cholangio carcinoma - BC-LM, Breast cancer liver metastases - CRC-LM, Colorectal carcinoma liver metastases - U-LM, Uveal liver metastases - CR, Complete response - PR, Partial response.

“ Data analysis showed an improvement of physical and social functioning, as well as better health perception one month after chemoembolization.¹ ”

“ No abdominal pain was recorded¹. ”

EVIDENCE: PROMISING RESULTS

In Hepatocellular Carcinoma (HCC)⁴

Forty-two patients with unresectable HCC were treated with 2ml of 100um LifePearl loaded with 50ml doxorubicin

TUMOUR RESPONSE

After 6-month follow up, the rates were:



TOLERABILITY

- TACE was well tolerated by all patients
- No evidence of procedure-related complications or systemic drug-related adverse events.
- No abdominal pain

QUALITY OF LIFE

- The QOL scores were 80 at 1 month, 81 at 3 months, and 82 at 6 months after TACE

Most frequent adverse events (grades 1 and 2):



“ These data suggest that PEG embolics are efficacious and safe for the treatment of HCC, as indicated by their good tolerability, QOL scores, and high tumor response. ”


In Cholangiocarcinoma (CCA)⁵

127 Cholangiocarcinoma patients with doxorubicin via DEM-TACE:

- 109 patients were treated with DC Bead (86%)
- 18 patients were treated with LifePearl (14%)

“ TACE was effective and safe for CCA treatment, with a high disease control rate. The best response of LifePearl was Partial Response, whereas it was Stable Disease for DEB-TACE. ”

Tumor response after 3 months of therapy



AT THE FRONT OF **INTERVENTIONAL ONCOLOGY WITH YOU**






1. Camillo Aliberti et al. Hepatic arterial infusion of polyethylene Glycol drug-eluting beads for primary and metastatic liver cancer therapy. *Anticancer Research* 36: 3515-3522(2016)
2. Philippe L. Pereira et al. An in-vitro evaluation of three types of drug-eluting microspheres loaded with irinotecan. *Anti-Cancer Drugs* (2016)
3. Thierry de Baere et al. An in vitro evaluation of four types of drug-eluting microspheres loaded with doxorubicin. *J Vasc Interv Radiol* (2016)
4. Aliberti et al. *AJR* 2017; 209 1-5
5. Camillo Aliberti et al. *ANTICANCER RESEARCH* 37: 1859-1863 (2017)

LifePearl®

Microspheres



ORDERING INFORMATION

LifePearl Sizes (µm)	Volume of Microspheres (ml)	Volume of PBS (ml)	Product Codes	Colour
100 ± 25	2	4	8LP2S100	Black 
200 ± 50	2	4	8LP2S200	Yellow 
400 ± 50	2	4	8LP2S400	Blue 

TERUMO
INTERVENTIONAL
SYSTEMS

Terumo Corporation
+81333748111

Terumo Europe NV
+3216381211

**Terumo
Interventional Systems EMEA**
+3216381211

EMEA Sales Offices

**Terumo Europe NV
Africa Business Division**
+3216381308

www.terumo-europe.com

**Terumo Europe NV
BeNeLux Sales Division**
Belgium:
0800 14468
The Netherlands:
0800 0231938

**Terumo Europe NV
Emerging Market Division**
+3216381211

Terumo Deutschland GmbH
+49 6196 80 230

**Terumo Deutschland GmbH
Österreich**
+43 2236 378020

**Terumo Deutschland GmbH
Switzerland**
+41 56 419 10 10

Terumo Europe España SL
+34 902 10 12 98

Terumo France S.A.S.
+33 130 96 13 00

Terumo Italia S.r.l.
+39 06 94 80 28 00

Terumo Russia LLC
+7 495 988 4740

Terumo Sweden AB
+46 3174 85 880

Terumo Middle East FZE
+971 4 292 0200

Terumo UK Ltd
+44 1276 480 440

**Terumo BCT Tıbbi Cihazlar Dağıtım
ve Hizmetleri A.Ş.**
+90 216 645 92 00



© Registered Trademark
Published by Terumo Europe NV

15514GB0415SCH1100717E